首页 > 最新文献

Revista Espa?ola de Medicina Nuclear (English Edition)最新文献

英文 中文
Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake 罗格列酮再分化治疗分化型甲状腺癌伴肺转移和放射性碘摄取缺失1例
Pub Date : 2011-07-01 DOI: 10.1016/j.remngl.2010.08.001
M. Elola , A. Yoldi , J.I. Emparanza , T. Matteucci , I. Bilbao , M. Goena

Treatment with radioiodine (RDI) has been shown to be an effective option in patients with differentiated thyroid cancer with recurrent or metastatic disease. However, in spite of having elevated levels of thyroglobulin in blood, in some of these patients, the whole body scan does not detect radioiodine uptake due to loss of differentiation of the neoplastic cells, thus leading to loss of efficacy of the treatment. That is why drugs with potential differentiating properties, like rosiglitazone or retinoids, are being studied. The aim of these drugs is to improve RDI uptake by the tumor cells. In this work, we have described the case of a patient in whom uptake of RDI by the pulmonary metastases, with subsequent decrease of their size, was achieved after treatment with rosiglitazone (8 mg/day for 2 months) as redifferentation therapy.

放射性碘(RDI)治疗已被证明是分化型甲状腺癌复发或转移性疾病患者的有效选择。然而,尽管血液中甲状腺球蛋白水平升高,但在其中一些患者中,由于肿瘤细胞分化丧失,全身扫描无法检测到放射性碘的摄取,从而导致治疗效果丧失。这就是为什么人们正在研究具有潜在分化特性的药物,如罗格列酮或类维甲酸。这些药物的目的是提高肿瘤细胞对RDI的吸收。在这项工作中,我们描述了一个患者的病例,在使用罗格列酮(8mg /天,持续2个月)作为再分化治疗后,肺转移灶吸收RDI,随后其体积减小。
{"title":"Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake","authors":"M. Elola ,&nbsp;A. Yoldi ,&nbsp;J.I. Emparanza ,&nbsp;T. Matteucci ,&nbsp;I. Bilbao ,&nbsp;M. Goena","doi":"10.1016/j.remngl.2010.08.001","DOIUrl":"10.1016/j.remngl.2010.08.001","url":null,"abstract":"<div><p>Treatment with radioiodine (RDI) has been shown to be an effective option in patients with differentiated thyroid cancer with recurrent or metastatic disease. However, in spite of having elevated levels of thyroglobulin in blood, in some of these patients, the whole body scan does not detect radioiodine uptake due to loss of differentiation of the neoplastic cells, thus leading to loss of efficacy of the treatment. That is why drugs with potential differentiating properties, like rosiglitazone or retinoids, are being studied. The aim of these drugs is to improve RDI uptake by the tumor cells. In this work, we have described the case of a patient in whom uptake of RDI by the pulmonary metastases, with subsequent decrease of their size, was achieved after treatment with rosiglitazone (8<!--> <!-->mg/day for 2 months) as redifferentation therapy.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.remngl.2010.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89316155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Sentinel node biopsy in patients with breast cancer and previous breast surgery 前哨淋巴结活检在乳腺癌患者和既往乳房手术
Pub Date : 2011-07-01 DOI: 10.1016/j.remngl.2011.03.001
I. Blanco , D. Díaz , C. Moriyón , L. Santamaría , M.A. Díez , M.T. López , H. Padín , F. Cantero , S. Artime , F. Domínguez , F.J. Aira , R. Álvarez-Obregón

Aim

The aim of this study was to establish the efficacy and safety of sentinel lymph node biopsy for lymph node staging in patients with breast cancer and prior breast surgery, considering its extension, localization and time since the previous surgical procedure.

Materials and methods

A sentinel lymph node biopsy was performed in 38 patients with early breast cancer and previous breast surgery: recent excisional biopsy in 22 patients (Group I), previous lumpectomy or mammoplasty in 16, including one case of cancer treated with breast-conserving surgery (tumor recurrence). Lymphoscintigraphy was performed after periareolar injection, also sometimes adding an injection near to the surgical scar. After removing the sentinel node, axillary lymph node dissection was performed when the lymph node was positive (and not localized).

Results

The efficacy of the scintigraphic localization of the sentinel node was 92.1% of the patients, with 15.8% of extra-axillary drainages. Axillary intraoperative detection was 81.6%. The identification rate after recent excisional biopsy or previous surgery was similar (81.8 vs 81.2%). However, extra-axillary sentinel nodes were more frequent in Group II (9.1 vs 25%). Having a localization of previous surgical procedures in upper outer quadrant caused drainages outside of the axilla more frequently (27.2 vs 11.1%). Axillary detection rate was similar to other quadrants (81.8 vs 81.5%). The rate of breast cancer-related events was 5.2% (2/38), without axillary recurrences (mean follow-up: 3 years).

Conclusion

Sentinel lymph node biopsy in patients with previous but not extensive breast surgery is safe. Extra-axillary drainages are more common when the previous surgical area was wide, especially in the upper-outer quadrant.

目的本研究的目的是建立前哨淋巴结活检对乳腺癌和既往乳房手术患者淋巴结分期的有效性和安全性,考虑其延伸、定位和时间。材料与方法对38例早期乳腺癌及既往乳房手术患者行前哨淋巴结活检:近期切除活检22例(I组),既往乳房肿瘤切除术或乳房成形术16例,其中保乳手术1例(肿瘤复发)。在乳晕周围注射后进行淋巴显影,有时也在手术疤痕附近进行注射。切除前哨淋巴结后,当淋巴结呈阳性(未定位)时进行腋窝淋巴结清扫。结果前哨淋巴结扫描定位有效率92.1%,腋外引流15.8%。术中腋窝检出率为81.6%。近期切除活检或既往手术后的检出率相似(81.8% vs 81.2%)。然而,第二组腋窝外前哨淋巴结发生率更高(9.1% vs 25%)。以前的手术定位在上外象限导致腋窝外引流更频繁(27.2% vs 11.1%)。腋窝检出率与其他象限相似(81.8 vs 81.5%)。乳腺癌相关事件发生率为5.2%(2/38),无腋窝复发(平均随访3年)。结论前哨淋巴结活检对既往未做过广泛乳房手术的患者是安全的。腋外引流在既往手术面积较宽时更为常见,尤其是在上外象限。
{"title":"Sentinel node biopsy in patients with breast cancer and previous breast surgery","authors":"I. Blanco ,&nbsp;D. Díaz ,&nbsp;C. Moriyón ,&nbsp;L. Santamaría ,&nbsp;M.A. Díez ,&nbsp;M.T. López ,&nbsp;H. Padín ,&nbsp;F. Cantero ,&nbsp;S. Artime ,&nbsp;F. Domínguez ,&nbsp;F.J. Aira ,&nbsp;R. Álvarez-Obregón","doi":"10.1016/j.remngl.2011.03.001","DOIUrl":"10.1016/j.remngl.2011.03.001","url":null,"abstract":"<div><h3>Aim</h3><p>The aim of this study was to establish the efficacy and safety of sentinel lymph node biopsy for lymph node staging in patients with breast cancer and prior breast surgery, considering its extension, localization and time since the previous surgical procedure.</p></div><div><h3>Materials and methods</h3><p>A sentinel lymph node biopsy was performed in 38 patients with early breast cancer and previous breast surgery: recent excisional biopsy in 22 patients (Group I), previous lumpectomy or mammoplasty in 16, including one case of cancer treated with breast-conserving surgery (tumor recurrence). Lymphoscintigraphy was performed after periareolar injection, also sometimes adding an injection near to the surgical scar. After removing the sentinel node, axillary lymph node dissection was performed when the lymph node was positive (and not localized).</p></div><div><h3>Results</h3><p>The efficacy of the scintigraphic localization of the sentinel node was 92.1% of the patients, with 15.8% of extra-axillary drainages. Axillary intraoperative detection was 81.6%. The identification rate after recent excisional biopsy or previous surgery was similar (81.8 vs 81.2%). However, extra-axillary sentinel nodes were more frequent in Group II (9.1 vs 25%). Having a localization of previous surgical procedures in upper outer quadrant caused drainages outside of the axilla more frequently (27.2 vs 11.1%). Axillary detection rate was similar to other quadrants (81.8 vs 81.5%). The rate of breast cancer-related events was 5.2% (2/38), without axillary recurrences (mean follow-up: 3 years).</p></div><div><h3>Conclusion</h3><p>Sentinel lymph node biopsy in patients with previous but not extensive breast surgery is safe. Extra-axillary drainages are more common when the previous surgical area was wide, especially in the upper-outer quadrant.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.remngl.2011.03.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90687023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Interobserver agreement in the visual and semi-quantitative analysis of the 123I-FP-CIT SPECT images in the diagnosis of Parkinsonian syndrome 1234 - fp - cit SPECT图像在帕金森综合征诊断中的视觉和半定量分析观察者间的一致性
Pub Date : 2011-07-01 DOI: 10.1016/j.remngl.2011.02.001
M. Suárez-Piñera , M.L. Prat , A. Mestre-Fusco , J. Fuertes , S. Mojal , E. Balaguer

Aims

Using 123I-FP-CIT SPECT images makes it possible to identify presynaptic deterioration of the dopaminergic pathway by studying the dopamine transporter (DAT). A correct analysis of the SPECT images contributes to an adequate interpretation and diagnosis of movement disorders. Aims: 1. To compare visual and semiquantitative analysis of 123I-FP-CIT SPECT images in patients with movement disorders. 2. To evaluate interobserver agreement in visual and semiquantitative analysis. 3. To obtain a cut-off in the semiquantitative analysis to discriminate primary Parkinsonism Syndrome (PS) from non-primary PS.

Methods

A 123I-FP-CIT SPECT was performed in 32 patients with movement disorders suggestive of primary PS. Visual and semiquantitative images analyses were performed independently by two nuclear medicine physicians. Visual analysis was based on the visual interpretation. Semiquantitative analysis was calculated as specific uptake (caudate, putamen and striatum) versus non-specific uptake (occipital). Sensitivity, specificity, PPV, and NPV were calculated. Data were compared using ANOVA test followed by Bonferroni post hoc test. Interobserver agreement of the visual and semiquantitative analysis was assessed by intraclass correlation coefficient and Kappa statistics, respectively. ROC curve was generated with semiquantitative data.

Results

Visual analysis showed 86% sensitivity and 100–88% specificity for the differential diagnosis of primary PS from non-primary PS. Semiquantitative analysis showed a gradual hypouptake proportional to the disease severity obtained in the visual analysis. Semiquantitative analysis did not provide any additional information to the visual analysis. Intraclass correlation coefficient and Kappa statistics showed 0.92 and 0.80 values, respectively. The cut-off value to differentiate primary PS from non-primary PS was 1.9 on the putamen index.

目的利用123I-FP-CIT SPECT图像,通过研究多巴胺转运体(DAT)来识别突触前多巴胺能通路的退化。SPECT图像的正确分析有助于运动障碍的充分解释和诊断。目的:1。比较运动障碍患者123I-FP-CIT SPECT图像的视觉和半定量分析。2. 评估观察者之间在视觉和半定量分析中的一致性。3.方法对32例提示原发性帕金森综合征(PS)的运动障碍患者行123I-FP-CIT SPECT检查,由2名核医学医师独立进行视觉和半定量图像分析。目视分析以目视解释为基础。半定量分析计算为特异性摄取(尾状核、壳核和纹状体)与非特异性摄取(枕状)。计算敏感性、特异性、PPV和NPV。数据比较采用方差分析和Bonferroni事后检验。分别用类内相关系数和Kappa统计量评估视觉和半定量分析的观察者间一致性。采用半定量数据生成ROC曲线。结果视觉分析显示,原发性PS与非原发性PS鉴别诊断的敏感性为86%,特异性为100-88%。半定量分析显示,视觉分析得出的疾病严重程度逐渐降低。半定量分析没有提供任何额外的信息,以视觉分析。类内相关系数和Kappa统计量分别为0.92和0.80。壳核指数区分原发性PS与非原发性PS的临界值为1.9。
{"title":"Interobserver agreement in the visual and semi-quantitative analysis of the 123I-FP-CIT SPECT images in the diagnosis of Parkinsonian syndrome","authors":"M. Suárez-Piñera ,&nbsp;M.L. Prat ,&nbsp;A. Mestre-Fusco ,&nbsp;J. Fuertes ,&nbsp;S. Mojal ,&nbsp;E. Balaguer","doi":"10.1016/j.remngl.2011.02.001","DOIUrl":"https://doi.org/10.1016/j.remngl.2011.02.001","url":null,"abstract":"<div><h3>Aims</h3><p>Using <sup>123</sup>I-FP-CIT SPECT images makes it possible to identify presynaptic deterioration of the dopaminergic pathway by studying the dopamine transporter (DAT). A correct analysis of the SPECT images contributes to an adequate interpretation and diagnosis of movement disorders. <em>Aims: 1.</em> To compare visual and semiquantitative analysis of <sup>123</sup>I-FP-CIT SPECT images in patients with movement disorders. <em>2.</em> To evaluate interobserver agreement in visual and semiquantitative analysis. <em>3.</em> To obtain a cut-off in the semiquantitative analysis to discriminate primary Parkinsonism Syndrome (PS) from non-primary PS.</p></div><div><h3>Methods</h3><p>A <sup>123</sup>I-FP-CIT SPECT was performed in 32 patients with movement disorders suggestive of primary PS. Visual and semiquantitative images analyses were performed independently by two nuclear medicine physicians. Visual analysis was based on the visual interpretation. Semiquantitative analysis was calculated as specific uptake (caudate, putamen and striatum) versus non-specific uptake (occipital). Sensitivity, specificity, PPV, and NPV were calculated. Data were compared using ANOVA test followed by Bonferroni post hoc test. Interobserver agreement of the visual and semiquantitative analysis was assessed by intraclass correlation coefficient and Kappa statistics, respectively. ROC curve was generated with semiquantitative data.</p></div><div><h3>Results</h3><p>Visual analysis showed 86% sensitivity and 100–88% specificity for the differential diagnosis of primary PS from non-primary PS. Semiquantitative analysis showed a gradual hypouptake proportional to the disease severity obtained in the visual analysis. Semiquantitative analysis did not provide any additional information to the visual analysis. Intraclass correlation coefficient and Kappa statistics showed 0.92 and 0.80 values, respectively. The cut-off value to differentiate primary PS from non-primary PS was 1.9 on the putamen index.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.remngl.2011.02.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136900348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reversible brain perfusion changes in an acute depersonalization syndrome. Role of SPECT with 99mTc-ECD 急性人格解体综合征的可逆性脑灌注改变。SPECT与99mTc-ECD的作用
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70008-0
J. Serrano Vicente, L. García Bernardo, C. Durán Barquero, J.I. Rayo Madrid, J.R. Infante Torre, M.L. Domínguez Grande, J.R. Gutiérrez Casares
{"title":"Reversible brain perfusion changes in an acute depersonalization syndrome. Role of SPECT with 99mTc-ECD","authors":"J. Serrano Vicente,&nbsp;L. García Bernardo,&nbsp;C. Durán Barquero,&nbsp;J.I. Rayo Madrid,&nbsp;J.R. Infante Torre,&nbsp;M.L. Domínguez Grande,&nbsp;J.R. Gutiérrez Casares","doi":"10.1016/S1578-200X(11)70008-0","DOIUrl":"10.1016/S1578-200X(11)70008-0","url":null,"abstract":"","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70008-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86941920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors 双时间点18F-FDOPA PET作为表征脑肿瘤的工具
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70012-2
M. González-Forero, E. Prieto, I. Domínguez, C. Vigil, I. Peñuelas, J. Arbizu

18F-FDOPA is an amino acid analogue used to evaluate presynaptic dopaminergic activity, which has aroused great interest in neuro-oncology. We have evaluated five 18F-FDOPA PET studies of patients referred for study of parkinsonian syndrome. Two subjects had previously treated high- grade brain tumors, one nonspecific brain injury, and 2 subjects presented unexpected tumoral lesions. For all lesions SUVmax, time to SUVmax and tumor-to-normal grey matter SUVmax rate (T/N) were calculated, and 90 minutes 18F-FDOPA kinetics were analyzed. Tumor lesions corresponded to three malignant neurocytomas, one meningioma, one pineocytoma and one intrasinusal heman- gioma. Both malignant and benign tumors exhibited high uptake of 18F-FDOPA well above the normal cortex. However, the analysis of the curve uptake displayed characteristic patterns that facilitate the characterization of tumor lesions. A dual phase maximum uptake was observed, with an early 10 minutes uptake in malignant lesions, and a late 60 to 90 minutes uptake in benign or low grade lesions.

18F-FDOPA是一种用于评估突触前多巴胺能活性的氨基酸类似物,在神经肿瘤学领域引起了极大的兴趣。我们评估了5例帕金森综合征患者的18F-FDOPA PET研究。两名受试者先前治疗过高度脑肿瘤,一名非特异性脑损伤,2名受试者出现意外的肿瘤病变。对所有病变SUVmax,计算SUVmax时间和肿瘤与正常灰质SUVmax比率(T/N),分析90分钟18F-FDOPA动力学。肿瘤病变对应3例恶性神经细胞瘤、1例脑膜瘤、1例松果体细胞瘤和1例鼻内血管瘤。恶性和良性肿瘤均表现出18F-FDOPA的高摄取,远高于正常皮层。然而,对曲线摄取的分析显示了有助于肿瘤病变表征的特征模式。观察到双期最大摄取,恶性病变早10分钟摄取,良性或低级别病变晚60至90分钟摄取。
{"title":"Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors","authors":"M. González-Forero,&nbsp;E. Prieto,&nbsp;I. Domínguez,&nbsp;C. Vigil,&nbsp;I. Peñuelas,&nbsp;J. Arbizu","doi":"10.1016/S1578-200X(11)70012-2","DOIUrl":"https://doi.org/10.1016/S1578-200X(11)70012-2","url":null,"abstract":"<div><p><sup>18</sup>F-FDOPA is an amino acid analogue used to evaluate presynaptic dopaminergic activity, which has aroused great interest in neuro-oncology. We have evaluated five <sup>18</sup>F-FDOPA PET studies of patients referred for study of parkinsonian syndrome. Two subjects had previously treated high- grade brain tumors, one nonspecific brain injury, and 2 subjects presented unexpected tumoral lesions. For all lesions SUVmax, time to SUVmax and tumor-to-normal grey matter SUVmax rate (T/N) were calculated, and 90 minutes <sup>18</sup>F-FDOPA kinetics were analyzed. Tumor lesions corresponded to three malignant neurocytomas, one meningioma, one pineocytoma and one intrasinusal heman- gioma. Both malignant and benign tumors exhibited high uptake of <sup>18</sup>F-FDOPA well above the normal cortex. However, the analysis of the curve uptake displayed characteristic patterns that facilitate the characterization of tumor lesions. A dual phase maximum uptake was observed, with an early 10 minutes uptake in malignant lesions, and a late 60 to 90 minutes uptake in benign or low grade lesions.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70012-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91598064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Takotsubo syndrome. Usefulness of Nuclear Medicine studies Takotsubo综合症。核医学研究的有用性
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70015-8
L.M. Mena , F. Martín , A. Melero , A. Ramos , I.R. Jiménez

Takotsubo syndrome can mimic an acute myocardial infarction. It is characterized by anginal chest pain with ST elevation in precordial leads, no coronary obstruction on angiography, and typical and reversible deformation of the left ventricular due to antero-apical ballooning with basal hyperkinesis. The pathophysiology of this syndrome is uncertain. It is probably multifactorial, cardiac adrenergic nervous dysfunction standing out in the acute phase. We report two cases performed within the diagnostic context of Takotsubo syndrome. Cardiac SPECT was performed using 123I Metaiodobenzlguanidine (MIBG) and 99mTc-Tetrofosmin and the results of two cases were adrenergic denervation in the anterior wall without alterations in myocardial perfusion study. Identification of Takotsubo syndrome is of clinical importance because its management and prognosis differ significantly from that of acute myocardial infarction.

Takotsubo综合征可以模拟急性心肌梗死。其特征为心绞痛性胸痛,心前导联ST段抬高,血管造影无冠状动脉阻塞,心尖前球囊伴基底运动亢进导致典型且可逆的左心室变形。该综合征的病理生理学尚不清楚。它可能是多因素的,心脏肾上腺素能性神经功能障碍在急性期突出。我们报告在Takotsubo综合征的诊断背景下进行的两个病例。采用123I Metaiodobenzlguanidine (MIBG)和99mTc-Tetrofosmin进行心脏SPECT, 2例心肌灌注研究结果均为前壁肾上腺素能失神经支配,心肌灌注研究未见改变。Takotsubo综合征的诊断具有重要的临床意义,因为其治疗和预后与急性心肌梗死有很大的不同。
{"title":"Takotsubo syndrome. Usefulness of Nuclear Medicine studies","authors":"L.M. Mena ,&nbsp;F. Martín ,&nbsp;A. Melero ,&nbsp;A. Ramos ,&nbsp;I.R. Jiménez","doi":"10.1016/S1578-200X(11)70015-8","DOIUrl":"https://doi.org/10.1016/S1578-200X(11)70015-8","url":null,"abstract":"<div><p>Takotsubo syndrome can mimic an acute myocardial infarction. It is characterized by anginal chest pain with ST elevation in precordial leads, no coronary obstruction on angiography, and typical and reversible deformation of the left ventricular due to antero-apical ballooning with basal hyperkinesis. The pathophysiology of this syndrome is uncertain. It is probably multifactorial, cardiac adrenergic nervous dysfunction standing out in the acute phase. We report two cases performed within the diagnostic context of Takotsubo syndrome. Cardiac SPECT was performed using <sup>123</sup>I Metaiodobenzlguanidine (MIBG) and <sup>99m</sup>Tc-Tetrofosmin and the results of two cases were adrenergic denervation in the anterior wall without alterations in myocardial perfusion study. Identification of Takotsubo syndrome is of clinical importance because its management and prognosis differ significantly from that of acute myocardial infarction.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70015-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91598067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
18F-FDG PET/CT with retrograde filling of the urinary bladder in the assessment of malignant pelvic disease 18F-FDG PET/CT伴膀胱逆行充盈对恶性盆腔病的评价
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70009-2
A.M. García Vicente, A. Núñez García, A. Palomar Muñoz, J.P. Pilkington Woll, M.E. Bellón Guardia, B. González García, A. Soriano Castrejón

Aim

To assess the role of PET/CT with retrograde filling of urinary bladder (RFUB) in the assessment of pelvic malignancy in patients with urothelial or gynecological tumors.

Material and methods

A retrospective longitudinal analysis based on 62 studies belonging to 52 patients was performed. All of them had a history of pelvic malignancy (29 urothelial and 23 gynecological) and 42 had undergone previous treatments. All patients underwent a standard PET/CT protocol. Inclusion criteria were radiological alterations in pelvic organs or increased urinary activity of 18F-FDG that hindered evaluation of the pelvic structures. Pathological pelvic locations were assessed as the additional value of PET/CT with RFUB. The pathologic lesions were histologically or clinically evaluated with a minimum follow-up of 12 months.

Results

Pelvic malignancy was confirmed in 33 cases, 16 of which were of urothelial origin. A total of 35/62 studies showed a pathologic PET/CT in pelvis, 4 of them were false positive and 2 false negative. In 19 cases, malignancy was detected in the bladder wall, 16 of which were true positive. No false negative was detected. Regarding standard imaging acquisition, RFUB helped to confirm or rule out bladder and/or gynecological disease in 54 cases.

Conclusion

Retrograde bladder filling is a highly recommended technique in the assessment of malignant pelvic disease, especially of bladder origin.

目的探讨PET/CT逆行膀胱充血(RFUB)在泌尿上皮或妇科肿瘤患者盆腔恶性肿瘤诊断中的价值。材料与方法对52例患者的62项研究进行回顾性纵向分析。所有患者均有盆腔恶性肿瘤病史(29例泌尿系,23例妇科),42例既往治疗。所有患者均接受标准PET/CT检查。纳入标准是盆腔器官的影像学改变或18F-FDG的尿活性增加,这阻碍了盆腔结构的评估。病理盆腔位置作为RFUB的PET/CT附加价值进行评估。病理病变进行组织学或临床评估,至少随访12个月。结果33例确诊为盆腔恶性肿瘤,其中16例来源于尿路上皮。62例研究中有35例显示骨盆病理PET/CT,其中4例假阳性,2例假阴性。19例膀胱壁检出恶性肿瘤,其中16例为真阳性。未检测到假阴性。在标准影像采集方面,54例RFUB帮助确诊或排除膀胱和/或妇科疾病。结论膀胱逆行填充术是评价恶性盆腔疾病,尤其是膀胱源性盆腔疾病的有效方法。
{"title":"18F-FDG PET/CT with retrograde filling of the urinary bladder in the assessment of malignant pelvic disease","authors":"A.M. García Vicente,&nbsp;A. Núñez García,&nbsp;A. Palomar Muñoz,&nbsp;J.P. Pilkington Woll,&nbsp;M.E. Bellón Guardia,&nbsp;B. González García,&nbsp;A. Soriano Castrejón","doi":"10.1016/S1578-200X(11)70009-2","DOIUrl":"10.1016/S1578-200X(11)70009-2","url":null,"abstract":"<div><h3>Aim</h3><p>To assess the role of PET/CT with retrograde filling of urinary bladder (RFUB) in the assessment of pelvic malignancy in patients with urothelial or gynecological tumors.</p></div><div><h3>Material and methods</h3><p>A retrospective longitudinal analysis based on 62 studies belonging to 52 patients was performed. All of them had a history of pelvic malignancy (29 urothelial and 23 gynecological) and 42 had undergone previous treatments. All patients underwent a standard PET/CT protocol. Inclusion criteria were radiological alterations in pelvic organs or increased urinary activity of <sup>18</sup>F-FDG that hindered evaluation of the pelvic structures. Pathological pelvic locations were assessed as the additional value of PET/CT with RFUB. The pathologic lesions were histologically or clinically evaluated with a minimum follow-up of 12 months.</p></div><div><h3>Results</h3><p>Pelvic malignancy was confirmed in 33 cases, 16 of which were of urothelial origin. A total of 35/62 studies showed a pathologic PET/CT in pelvis, 4 of them were false positive and 2 false negative. In 19 cases, malignancy was detected in the bladder wall, 16 of which were true positive. No false negative was detected. Regarding standard imaging acquisition, RFUB helped to confirm or rule out bladder and/or gynecological disease in 54 cases.</p></div><div><h3>Conclusion</h3><p>Retrograde bladder filling is a highly recommended technique in the assessment of malignant pelvic disease, especially of bladder origin.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70009-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91201115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Treatment protocols and follow-up of differentiated thyroid carcinoma: results of a questionnaire sent to the Spanish Metabolic Therapy Units 分化型甲状腺癌的治疗方案和随访:发给西班牙代谢治疗单位的问卷调查结果
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70020-1
M.A. Muros , J. Arbizu , M.D. Abós , M. Mitjavilla , E. Caballero-Calabuig , J.A. Vallejo

Objective

To know the treatment and follow-up protocols of differentiated thyroid carcinoma patients in Spanish Metabolic Therapy Units, the clinical variability between them and the adaptation to the consensus guidelines.

Materials and methods

Analysis of the results obtained from the questionnaire submitted by E-mail to the Spanish Society of Nuclear Medicine (SEMNIM) members on the treatment and follow-up of differentiated thyroid carcinoma patients. A descriptive study was made of the qualitative variables (frequency, percentage) and quantitative variables (mean, standard deviation).

Results

Twenty Radiometabolic Therapy Units responded to the questionnaire. In spite of the varied origin of the patients, the Units receive sufficient clinical information and have specialized surgeons. There is variability in the surgical protocols and indication for ablation in patients with intermediate and low risk of recurrence. The Units agree on the use of 131I doses for ablation and therapy, but show great variability regarding the preparation protocols (previous 131I-whole body scan or other imaging techniques, 131I-whole body scan dose, diet and radioiodine contrast prohibition, total dose per patient). Nuclear Medicine physicians perceive radioiodine adverse effects and prevention methods are used. The post-ablation follow-up protocol differs between Units.

Conclusions

Treatment and follow-up protocols of differentiated thyroid carcinoma patients in the Spanish Radiometabolic Therapy Units show variability in aspects such as surgery and ablation indications, patient preparation for radioiodine therapy and follow-up. Our clinical practice differs in several aspects from the recent consensus guideline recommendations.

目的了解西班牙代谢治疗单位分化型甲状腺癌患者的治疗及随访方案、临床差异及对共识指南的适应情况。材料与方法通过电子邮件向西班牙核医学学会(SEMNIM)会员提交关于分化型甲状腺癌患者治疗与随访的问卷调查结果进行分析。对定性变量(频率、百分比)和定量变量(均值、标准差)进行描述性研究。结果20家放射代谢治疗单位参与了问卷调查。尽管病人来自不同的地方,但这些单位获得了充分的临床资料,并有专门的外科医生。中低复发风险患者的手术方案和适应症存在差异。各单位同意使用131I剂量进行消融和治疗,但在制备方案方面存在很大差异(先前的131I全身扫描或其他成像技术,131I全身扫描剂量,饮食和放射性碘造影剂禁止,每位患者总剂量)。核医学医生认识到放射性碘的不良影响并采用预防方法。消融后随访方案各科室不同。结论西班牙放射代谢治疗单位对分化型甲状腺癌患者的治疗和随访方案在手术和消融指征、患者放射碘治疗准备和随访等方面存在差异。我们的临床实践在几个方面不同于最近的共识指南建议。
{"title":"Treatment protocols and follow-up of differentiated thyroid carcinoma: results of a questionnaire sent to the Spanish Metabolic Therapy Units","authors":"M.A. Muros ,&nbsp;J. Arbizu ,&nbsp;M.D. Abós ,&nbsp;M. Mitjavilla ,&nbsp;E. Caballero-Calabuig ,&nbsp;J.A. Vallejo","doi":"10.1016/S1578-200X(11)70020-1","DOIUrl":"https://doi.org/10.1016/S1578-200X(11)70020-1","url":null,"abstract":"<div><h3>Objective</h3><p>To know the treatment and follow-up protocols of differentiated thyroid carcinoma patients in Spanish Metabolic Therapy Units, the clinical variability between them and the adaptation to the consensus guidelines.</p></div><div><h3>Materials and methods</h3><p>Analysis of the results obtained from the questionnaire submitted by E-mail to the Spanish Society of Nuclear Medicine (SEMNIM) members on the treatment and follow-up of differentiated thyroid carcinoma patients. A descriptive study was made of the qualitative variables (frequency, percentage) and quantitative variables (mean, standard deviation).</p></div><div><h3>Results</h3><p>Twenty Radiometabolic Therapy Units responded to the questionnaire. In spite of the varied origin of the patients, the Units receive sufficient clinical information and have specialized surgeons. There is variability in the surgical protocols and indication for ablation in patients with intermediate and low risk of recurrence. The Units agree on the use of <sup>131</sup>I doses for ablation and therapy, but show great variability regarding the preparation protocols (previous <sup>131</sup>I-whole body scan or other imaging techniques, <sup>131</sup>I-whole body scan dose, diet and radioiodine contrast prohibition, total dose per patient). Nuclear Medicine physicians perceive radioiodine adverse effects and prevention methods are used. The post-ablation follow-up protocol differs between Units.</p></div><div><h3>Conclusions</h3><p>Treatment and follow-up protocols of differentiated thyroid carcinoma patients in the Spanish Radiometabolic Therapy Units show variability in aspects such as surgery and ablation indications, patient preparation for radioiodine therapy and follow-up. Our clinical practice differs in several aspects from the recent consensus guideline recommendations.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70020-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137257120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term results of treatment with 131I in patients with multinodular goiter: effect of the associated degree of hyperthyroidism and other variables 131I治疗多结节性甲状腺肿的短期疗效:甲状腺功能亢进相关程度及其他变量的影响
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70021-3
D. Boj Carceller , P. Liévano Segundo , P. Navarro Beltrán , A. Sanz París , P. de Castro Hernández , M. Monreal Villanueva , D. Abós Olivares

Objective

To assess the effectiveness of radioactive iodine (RAI) therapy and the incidence of hypothyroidism post RAI in patients with subclinical hyperthyroidism or clinical hyperthyroidism with Multinodular Goiter (MNG).

Methods

A retrospective study of 69 consecutive patients treated with 131I for MNG during the year 2008 observed for six months. All patients received a single fixed dose of 16 mCi (592 MBq) weighted by the gland size. They were categorized into two groups: subclinical hyperthyroidism or clinical hyperthyroidism. We compared the success rate and the incidence of hypothyroidism.

Results

The thyroid dysfunction was corrected in 82.09% of the patients. Success rate was 100% in the clinical hyperthyroidism group and 78.13% in the subclinical hyperthyroidism group (P = 0.105). The overall incidence of hypothyroidism was 16.42%; 25.00% of patients with clinical hyperthyroidism and 14.55% with subclinical hyperthyroidism developed this secondary effect (P = 0.400). No statistically significant differences were found in the success rate in the incidence of hypothyroidism when the results were analyzed according to the thyrotropin decrease in patients with subclinical hyperthyroidism. Seven patients had positive anti-thyroid peroxidase antibodies (anti-TPO) before therapy. The incidence of hypothyroidism was significantly higher in them (57.14% vs 11.67%; P = 0.011). Cardiac arrhythmias were four times more frequent in patients with clinical hyperthyroidism. Previous treatment with thiamazol positively affected the outcome.

Conclusions

A single fixed weighted dose of 131I is highly effective and safe for the control of clinical and subclinical hyperthyroidism due to MNG. Patients with anti-TPO antibodies may have a high risk of developing post-iodine hypothyroidism.

目的探讨放射性碘(RAI)治疗亚临床甲状腺机能亢进或临床甲状腺机能亢进合并多结节性甲状腺肿(MNG)患者的疗效及RAI后甲状腺功能减退的发生率。方法回顾性分析2008年连续69例使用131I治疗MNG的患者,观察6个月。所有患者均接受按腺体大小加权的单次固定剂量16 mCi (592 MBq)。他们被分为两组:亚临床甲状腺功能亢进和临床甲状腺功能亢进。我们比较了甲状腺功能减退的发生率和成功率。结果82.09%的患者甲状腺功能恢复正常。临床甲亢组的成功率为100%,亚临床甲亢组的成功率为78.13% (P = 0.105)。甲状腺功能减退的总发病率为16.42%;25.00%的临床甲亢患者和14.55%的亚临床甲亢患者出现了这种继发效应(P = 0.400)。根据亚临床甲状腺功能亢进患者促甲状腺素下降情况分析,两组治疗甲状腺功能减退的成功率差异无统计学意义。治疗前抗甲状腺过氧化物酶抗体(anti-TPO)阳性7例。甲状腺功能减退的发生率明显高于对照组(57.14% vs 11.67%;p = 0.011)。心律失常在临床甲状腺机能亢进患者中发生率高出4倍。以前用噻马索治疗对结果有积极影响。结论单次固定加权剂量131I治疗MNG所致临床及亚临床甲状腺功能亢进疗效高、安全性好。有抗tpo抗体的患者可能有较高的患碘后甲状腺功能减退的风险。
{"title":"Short-term results of treatment with 131I in patients with multinodular goiter: effect of the associated degree of hyperthyroidism and other variables","authors":"D. Boj Carceller ,&nbsp;P. Liévano Segundo ,&nbsp;P. Navarro Beltrán ,&nbsp;A. Sanz París ,&nbsp;P. de Castro Hernández ,&nbsp;M. Monreal Villanueva ,&nbsp;D. Abós Olivares","doi":"10.1016/S1578-200X(11)70021-3","DOIUrl":"10.1016/S1578-200X(11)70021-3","url":null,"abstract":"<div><h3>Objective</h3><p>To assess the effectiveness of radioactive iodine (RAI) therapy and the incidence of hypothyroidism post RAI in patients with subclinical hyperthyroidism or clinical hyperthyroidism with Multinodular Goiter (MNG).</p></div><div><h3>Methods</h3><p>A retrospective study of 69 consecutive patients treated with <sup>131</sup>I for MNG during the year 2008 observed for six months. All patients received a single fixed dose of 16 mCi (592<!--> <!-->MBq) weighted by the gland size. They were categorized into two groups: subclinical hyperthyroidism or clinical hyperthyroidism. We compared the success rate and the incidence of hypothyroidism.</p></div><div><h3>Results</h3><p>The thyroid dysfunction was corrected in 82.09% of the patients. Success rate was 100% in the clinical hyperthyroidism group and 78.13% in the subclinical hyperthyroidism group (P<!--> <!-->=<!--> <!-->0.105). The overall incidence of hypothyroidism was 16.42%; 25.00% of patients with clinical hyperthyroidism and 14.55% with subclinical hyperthyroidism developed this secondary effect (P<!--> <!-->=<!--> <!-->0.400). No statistically significant differences were found in the success rate in the incidence of hypothyroidism when the results were analyzed according to the thyrotropin decrease in patients with subclinical hyperthyroidism. Seven patients had positive anti-thyroid peroxidase antibodies (anti-TPO) before therapy. The incidence of hypothyroidism was significantly higher in them (57.14% vs 11.67%; P<!--> <!-->=<!--> <!-->0.011). Cardiac arrhythmias were four times more frequent in patients with clinical hyperthyroidism. Previous treatment with thiamazol positively affected the outcome.</p></div><div><h3>Conclusions</h3><p>A single fixed weighted dose of <sup>131</sup>I is highly effective and safe for the control of clinical and subclinical hyperthyroidism due to MNG. Patients with anti-TPO antibodies may have a high risk of developing post-iodine hypothyroidism.</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70021-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84431419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
False negative scintigraphy with 99mTc-sestamibi in parathyroid carcinoma with associated brown tumors. Contributions of 18F-FDG-PET/CT 甲状旁腺癌伴棕色肿瘤99mTc-sestamibi的假阴性显像。18F-FDG-PET/CT的贡献
Pub Date : 2011-01-01 DOI: 10.1016/S1578-200X(11)70024-9
A. Santiago Chinchilla, C. Ramos Font, M.A. Muros de Fuentes, M. Navarro-Pelayo Láinez, H. Palacios Gerona, M. Moreno Caballero, J.M. Llamas Elvira

Parathyroid carcinoma (PTC) is a rare malignant disease that is usually hyperfunctioning, which produces an excess of parathyroid hormone. Hyperparathyroidism causes bone metabolism disorders, as osteopenia and sometimes brown tumors. Brown tumors are benign but locally aggressive bone lesions, whose differential diagnosis with metastases or other primary malignancies may be complicated. 99mTc- Sestamibi scan is the usual procedure for the detection of parathyroid pathology, with a sensitivity of 85–100% and specificity close to 100% in parathyroid adenomas, it having similar percentages in the detection of PTC. We present the case of a patient diagnosed of a malignant hyperparathyroidism associated with bone lesions in which the 99mTc-Sestamibi scan showed a false negative result in the detection of parathyroid condition. However, 18F-FDG-PET/CT detected the PTC and helped in the differential diagnosis of associated bone lesions, which were finally confirmed as brown tumors

甲状旁腺癌(PTC)是一种罕见的恶性疾病,通常是功能亢进,产生过量的甲状旁腺激素。甲状旁腺功能亢进引起骨代谢紊乱,如骨质减少,有时还会引起棕色肿瘤。棕色肿瘤是良性的,但局部侵袭性骨病变,其与转移或其他原发性恶性肿瘤的鉴别诊断可能很复杂。99mTc- Sestamibi扫描是检测甲状旁腺病理的常用方法,甲状旁腺瘤的敏感性为85-100%,特异性接近100%,在PTC的检测中也有类似的百分比。我们提出的病例患者诊断为恶性甲状旁腺功能亢进与骨病变,其中99mTc-Sestamibi扫描显示假阴性结果在甲状旁腺疾病的检测。然而,18F-FDG-PET/CT检测到PTC,并帮助鉴别诊断相关的骨病变,最终确认为棕色肿瘤
{"title":"False negative scintigraphy with 99mTc-sestamibi in parathyroid carcinoma with associated brown tumors. Contributions of 18F-FDG-PET/CT","authors":"A. Santiago Chinchilla,&nbsp;C. Ramos Font,&nbsp;M.A. Muros de Fuentes,&nbsp;M. Navarro-Pelayo Láinez,&nbsp;H. Palacios Gerona,&nbsp;M. Moreno Caballero,&nbsp;J.M. Llamas Elvira","doi":"10.1016/S1578-200X(11)70024-9","DOIUrl":"10.1016/S1578-200X(11)70024-9","url":null,"abstract":"<div><p>Parathyroid carcinoma (PTC) is a rare malignant disease that is usually hyperfunctioning, which produces an excess of parathyroid hormone. Hyperparathyroidism causes bone metabolism disorders, as osteopenia and sometimes brown tumors. Brown tumors are benign but locally aggressive bone lesions, whose differential diagnosis with metastases or other primary malignancies may be complicated. 99mTc- Sestamibi scan is the usual procedure for the detection of parathyroid pathology, with a sensitivity of 85–100% and specificity close to 100% in parathyroid adenomas, it having similar percentages in the detection of PTC. We present the case of a patient diagnosed of a malignant hyperparathyroidism associated with bone lesions in which the 99mTc-Sestamibi scan showed a false negative result in the detection of parathyroid condition. However, 18F-FDG-PET/CT detected the PTC and helped in the differential diagnosis of associated bone lesions, which were finally confirmed as brown tumors</p></div>","PeriodicalId":101111,"journal":{"name":"Revista Espa?ola de Medicina Nuclear (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1578-200X(11)70024-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83923362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
期刊
Revista Espa?ola de Medicina Nuclear (English Edition)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1